Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

The influenza virus hemagglutinin head evolves faster than the stalk domain.

Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F.

Sci Rep. 2018 Jul 11;8(1):10432. doi: 10.1038/s41598-018-28706-1.

2.

Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers.

Das DK, Govindan R, Nikić-Spiegel I, Krammer F, Lemke EA, Munro JB.

Cell. 2018 Jun 21. pii: S0092-8674(18)30713-X. doi: 10.1016/j.cell.2018.05.050. [Epub ahead of print]

PMID:
29961575
3.

Influenza.

Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, García-Sastre A.

Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y. Review. No abstract available.

PMID:
29955068
4.

Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.

Stadlbauer D, Amanat F, Strohmeier S, Nachbagauer R, Krammer F.

Emerg Microbes Infect. 2018 Jun 20;7(1):110. doi: 10.1038/s41426-018-0115-0.

5.

Broadly-reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice from highly pathogenic H5N1 challenge.

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, Ellebedy AH.

J Virol. 2018 Jun 13. pii: JVI.00949-18. doi: 10.1128/JVI.00949-18. [Epub ahead of print]

PMID:
29899095
6.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

PMID:
29739835
7.

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses.

Amanat F, Duehr J, Oestereich L, Hastie KM, Ollmann Saphire E, Krammer F.

mSphere. 2018 May 2;3(3). pii: e00189-18. doi: 10.1128/mSphere.00189-18. eCollection 2018 May-Jun.

8.

Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?

Tan J, Asthagiri Arunkumar G, Krammer F.

Curr Opin Immunol. 2018 Apr 17;53:45-50. doi: 10.1016/j.coi.2018.04.002. [Epub ahead of print] Review.

PMID:
29677684
9.

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice.

Wang J, Hilchey SP, DeDiego M, Perry S, Hyrien O, Nogales A, Garigen J, Amanat F, Huertas N, Krammer F, Martinez-Sobrido L, Topham DJ, Treanor JJ, Sangster MY, Zand MS.

PLoS One. 2018 Apr 11;13(4):e0193680. doi: 10.1371/journal.pone.0193680. eCollection 2018.

10.

Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.

Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, Henry C, Palm AE, Stamper CT, Lan LY, Topham DJ, Treanor J, Wrammert J, Ahmed R, Eichelberger MC, Georgiou G, Krammer F, Wilson PC.

Cell. 2018 Apr 5;173(2):417-429.e10. doi: 10.1016/j.cell.2018.03.030.

PMID:
29625056
11.

An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.

Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F.

PLoS One. 2018 Apr 4;13(4):e0194830. doi: 10.1371/journal.pone.0194830. eCollection 2018.

12.

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS.

MBio. 2018 Apr 3;9(2). pii: e02332-17. doi: 10.1128/mBio.02332-17. Review.

13.

Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.

Isakova-Sivak I, Korenkov D, Smolonogina T, Kotomina T, Donina S, Matyushenko V, Mezhenskaya D, Krammer F, Rudenko L.

Virology. 2018 May;518:313-323. doi: 10.1016/j.virol.2018.03.013. Epub 2018 Mar 22.

PMID:
29574336
14.

Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.

Tete SM, Jul-Larsen Å, Rostami S, Lunde THF, Søland H, Krammer F, Cox RJ.

Vaccine. 2018 Apr 12;36(16):2213-2219. doi: 10.1016/j.vaccine.2018.02.022. Epub 2018 Mar 13.

PMID:
29548607
15.

H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Czakó R, Vogel L, Sutton T, Matsuoka Y, Krammer F, Chen Z, Jin H, Subbarao K.

Vaccine. 2018 Mar 27;36(14):1871-1879. doi: 10.1016/j.vaccine.2018.02.061. Epub 2018 Mar 1.

PMID:
29503113
16.

Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA, Vassilieva EV, Beaver JT, Antao O, Krammer F, Compans RW, Prausnitz MR, Skountzou I.

J Control Release. 2018 Apr 28;276:1-16. doi: 10.1016/j.jconrel.2018.02.033. Epub 2018 Feb 26.

17.

Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model.

Duehr J, Lee S, Singh G, Foster GA, Krysztof D, Stramer SL, Bermúdez González MC, Menichetti E, Geretschläger R, Gabriel C, Simon V, Lim JK, Krammer F.

mSphere. 2018 Feb 7;3(1). pii: e00011-18. doi: 10.1128/mSphereDirect.00011-18. eCollection 2018 Jan-Feb.

18.

Influenza B virus reverse genetic backbones with improved growth properties in the EB66® cell line as basis for vaccine seed virus generation.

White KM, Ayllon J, Mena I, Potenski A, Krammer F, García-Sastre A.

Vaccine. 2018 Feb 21;36(9):1146-1153. doi: 10.1016/j.vaccine.2018.01.050. Epub 2018 Feb 1.

PMID:
29395518
19.

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

de Vries RD, Nieuwkoop NJ, van der Klis FRM, Koopmans MPG, Krammer F, Rimmelzwaan GF.

J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546.

PMID:
29294018
20.

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.

Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F.

NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017.

21.

Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.

Van Reeth K, Gracia JCM, Trus I, Sys L, Claes G, Versnaeyen H, Cox E, Krammer F, Qiu Y.

NPJ Vaccines. 2017;2. pii: 11. doi: 10.1038/s41541-017-0012-x. Epub 2017 Apr 20.

22.

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.

Stadlbauer D, Rajabhathor A, Amanat F, Kaplan D, Masud A, Treanor JJ, Izikson R, Cox MM, Nachbagauer R, Krammer F.

mSphere. 2017 Dec 13;2(6). pii: e00502-17. doi: 10.1128/mSphere.00502-17. eCollection 2017 Nov-Dec.

23.

Development of an influenza virus protein microarray to measure the humoral response to influenza virus infection in mallards.

Meade P, Latorre-Margalef N, Stallknecht DE, Krammer F.

Emerg Microbes Infect. 2017 Dec 6;6(12):e110. doi: 10.1038/emi.2017.98.

24.

Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Stadlbauer D, Nachbagauer R, Meade P, Krammer F.

Front Med. 2017 Dec;11(4):471-479. doi: 10.1007/s11684-017-0602-z. Epub 2017 Nov 20. Review.

PMID:
29159597
25.

Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.

He W, Chen CJ, Mullarkey CE, Hamilton JR, Wong CK, Leon PE, Uccellini MB, Chromikova V, Henry C, Hoffman KW, Lim JK, Wilson PC, Miller MS, Krammer F, Palese P, Tan GS.

Nat Commun. 2017 Oct 10;8(1):846. doi: 10.1038/s41467-017-00928-3.

26.

Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication.

Kuss-Duerkop SK, Wang J, Mena I, White K, Metreveli G, Sakthivel R, Mata MA, Muñoz-Moreno R, Chen X, Krammer F, Diamond MS, Chen ZJ, García-Sastre A, Fontoura BMA.

PLoS Pathog. 2017 Sep 27;13(9):e1006635. doi: 10.1371/journal.ppat.1006635. eCollection 2017 Sep.

27.

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model.

Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R.

MBio. 2017 Sep 19;8(5). pii: e01463-17. doi: 10.1128/mBio.01463-17.

28.

Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody.

Chromikova V, Zaragoza MA, Krammer F.

PLoS One. 2017 Sep 14;12(9):e0183315. doi: 10.1371/journal.pone.0183315. eCollection 2017.

29.

Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.

Islam S, Mohn KG, Krammer F, Sanne M, Bredholt G, Jul-Larsen Å, Tete SM, Zhou F, Brokstad KA, Cox RJ.

Vaccine. 2017 Oct 9;35(42):5666-5673. doi: 10.1016/j.vaccine.2017.08.044. Epub 2017 Sep 9.

PMID:
28899626
30.

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies.

Leon PE, Wohlbold TJ, He W, Bailey MJ, Henry CJ, Wilson PC, Krammer F, Tan GS.

J Vis Exp. 2017 Aug 29;(126). doi: 10.3791/56067.

31.

From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Henry C, Palm AE, Krammer F, Wilson PC.

Trends Immunol. 2018 Jan;39(1):70-79. doi: 10.1016/j.it.2017.08.003. Epub 2017 Aug 31. Review.

PMID:
28867526
32.

Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.

Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, Amanat F, Tan J, tenOever BR, Tan GS, Subramaniam S, Palese P, Krammer F.

Nat Microbiol. 2017 Oct;2(10):1415-1424. doi: 10.1038/s41564-017-0011-8. Epub 2017 Aug 21.

33.

Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Goff PH, Hayashi T, He W, Yao S, Cottam HB, Tan GS, Crain B, Krammer F, Messer K, Pu M, Carson DA, Palese P, Corr M.

J Virol. 2017 Sep 12;91(19). pii: e01050-17. doi: 10.1128/JVI.01050-17. Print 2017 Oct 1.

34.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Krammer F, García-Sastre A, Palese P.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028845. doi: 10.1101/cshperspect.a028845. Review.

PMID:
28663209
35.

A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.

Paul SS, Mok CK, Mak TM, Ng OW, Aboagye JO, Wohlbold TJ, Krammer F, Tan YJ.

Antiviral Res. 2017 Aug;144:299-310. doi: 10.1016/j.antiviral.2017.06.012. Epub 2017 Jun 19.

PMID:
28633988
36.

Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Duehr J, Wohlbold TJ, Oestereich L, Chromikova V, Amanat F, Rajendran M, Gomez-Medina S, Mena I, tenOever BR, García-Sastre A, Basler CF, Munoz-Fontela C, Krammer F.

J Virol. 2017 Jul 27;91(16). pii: e00652-17. doi: 10.1128/JVI.00652-17. Print 2017 Aug 15.

37.

Stopping emerging influenza viruses at their origin.

Krammer F.

Lancet Infect Dis. 2017 Aug;17(8):784-786. doi: 10.1016/S1473-3099(17)30297-9. Epub 2017 May 19. No abstract available.

38.

An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses.

Holthausen DJ, Lee SH, Kumar VT, Bouvier NM, Krammer F, Ellebedy AH, Wrammert J, Lowen AC, George S, Pillai MR, Jacob J.

Immunity. 2017 Apr 18;46(4):587-595. doi: 10.1016/j.immuni.2017.03.018.

39.

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.

Liu L, Nachbagauer R, Zhu L, Huang Y, Xie X, Jin S, Zhang A, Wan Y, Hirsh A, Tian D, Shi X, Dong Z, Yuan S, Hu Y, Krammer F, Zhang X, Xu J.

J Infect Dis. 2017 Feb 15;215(4):518-528. doi: 10.1093/infdis/jiw608.

40.

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, García-Sastre A, Krammer F, Lim JK.

Science. 2017 Apr 14;356(6334):175-180. doi: 10.1126/science.aal4365. Epub 2017 Mar 30.

41.

Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.

Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F.

J Virol. 2017 May 26;91(12). pii: e00286-17. doi: 10.1128/JVI.00286-17. Print 2017 Jun 15.

42.

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Rajendran M, Nachbagauer R, Ermler ME, Bunduc P, Amanat F, Izikson R, Cox M, Palese P, Eichelberger M, Krammer F.

MBio. 2017 Mar 21;8(2). pii: e02281-16. doi: 10.1128/mBio.02281-16.

43.

A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses.

Tripathi S, Balasubramaniam VR, Brown JA, Mena I, Grant A, Bardina SV, Maringer K, Schwarz MC, Maestre AM, Sourisseau M, Albrecht RA, Krammer F, Evans MJ, Fernandez-Sesma A, Lim JK, García-Sastre A.

PLoS Pathog. 2017 Mar 9;13(3):e1006258. doi: 10.1371/journal.ppat.1006258. eCollection 2017 Mar.

44.

Strategies to induce broadly protective antibody responses to viral glycoproteins.

Krammer F.

Expert Rev Vaccines. 2017 May;16(5):503-513. doi: 10.1080/14760584.2017.1299576. Epub 2017 Mar 17. Review.

PMID:
28277797
45.

Universal influenza virus vaccines and therapeutic antibodies.

Nachbagauer R, Krammer F.

Clin Microbiol Infect. 2017 Apr;23(4):222-228. doi: 10.1016/j.cmi.2017.02.009. Epub 2017 Feb 12. Review.

46.

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM, Ito K, Medina RA, Palese P, Krammer F.

Nat Immunol. 2017 Apr;18(4):464-473. doi: 10.1038/ni.3684. Epub 2017 Feb 13.

47.

Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections.

Hall OJ, Nachbagauer R, Vermillion MS, Fink AL, Phuong V, Krammer F, Klein SL.

J Virol. 2017 Mar 29;91(8). pii: e02160-16. doi: 10.1128/JVI.02160-16. Print 2017 Apr 15.

48.

Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

de Vries RD, Nieuwkoop NJ, Pronk M, de Bruin E, Leroux-Roels G, Huijskens EGW, van Binnendijk RS, Krammer F, Koopmans MPG, Rimmelzwaan GF.

Vaccine. 2017 Jan 5;35(2):238-247. doi: 10.1016/j.vaccine.2016.11.082. Epub 2016 Nov 30.

PMID:
27914742
49.

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.

Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, Murrin EM, Chrysostomou C, Hoi KH, Tsybovsky Y, Thomas PV, Druz A, Zhang B, Zhang Y, Wang L, Kong WP, Park D, Popova LI, Dekker CL, Davis MM, Carter CE, Ross TM, Ellington AD, Wilson PC, Marcotte EM, Mascola JR, Ippolito GC, Krammer F, Quake SR, Kwong PD, Georgiou G.

Nat Med. 2016 Dec;22(12):1456-1464. doi: 10.1038/nm.4224. Epub 2016 Nov 7.

50.

Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats.

Beaty SM, Nachbagauer R, Hirsh A, Vigant F, Duehr J, Azarm KD, Stelfox AJ, Bowden TA, Duprex WP, Krammer F, Lee B.

J Infect Dis. 2017 Jan 15;215(2):209-213. doi: 10.1093/infdis/jiw534.

Supplemental Content

Loading ...
Support Center